Literature DB >> 30805977

Umbilical cord blood mesenchymal stem cells application in hematopoietic stem cells expansion on nanofiber three-dimensional scaffold.

Maryam Darvish1, Zahra Payandeh2, Fatemeh Soleimanifar3, Behnaz Taheri4, Masoud Soleimani5, Maryam Islami3.   

Abstract

Umbilical cord blood (UCB) hematopoietic stem cells (HSCs) transplantation (HSCTs) is considered as a therapeutic strategy for malignant and nonmalignant hematologic disorders. Nevertheless, the low number of HSCs obtained from each unit of UCB can be a major challenge for using these cells in adults. In addition, UCB is a rich source of mesenchymal stem cells (MSCs) creating hopes for nonaggressive and painless treatment in tissue engineering compared with bone marrow MSCs. This study was designed to evaluate the effects of UCB-MSCs application in UCB-HSCs expansion on the nanoscaffold that mimics the cell's natural niche. To achieve this goal, after flow cytometry confirmation of isolated HSCs from UCB, they were expanded on three-dimensional (3D) poly-l-lactic acid (PLLA) scaffolds fabricated by electrospinning and two-dimensional (2D)-culture systems, such as (1) HSCs-MSCs culturing on the scaffold, (2) HSCs culturing on the scaffold, (3) HSCs-MSCs culturing on 2D, and (4) HSCs culturing on 2D. After 7 days, real-time polymerase chain reaction (PCR) was performed to evaluate the CXCR4 gene expression in the mentioned groups. Moreover, for the next validation, the number of total HSCs, 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide assay, scanning electron microscopy imaging, and colony-forming unit assay were evaluated as well. The results of the study indicated that UCB-MSCs interaction with HSCs in 3D-culture systems led to the highest expansion of UCB-HSCs on day 7. Flow cytometry results showed the highest purity of HSCs cocultured with MSCs. Real-time PCR showed a significant increase in gene expression of CXCR4 in the mentioned group. The highest viability and clonogenicity were detected in the mentioned group too. Considered together, our results suggest that UCB-HSCs and MSCs coculturing on PLLA scaffold could provide a proper microenvironment that efficiently promotes UCB-HSCs expansion and UCB-MSCs can also be considered as a promising candidate for UCB-HSCTs.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  CD133+ cell; biodegradable scaffold; hematopoietic stem cells; mesenchymal stem cells; poly-l-lactic acid; transplantation; umbilical cord blood

Year:  2019        PMID: 30805977     DOI: 10.1002/jcb.28487

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  5 in total

Review 1.  Bone Marrow Niches of Hematopoietic Stem and Progenitor Cells.

Authors:  Oleg Kandarakov; Alexander Belyavsky; Ekaterina Semenova
Journal:  Int J Mol Sci       Date:  2022-04-18       Impact factor: 6.208

2.  Tailored Cytokine Optimization for ex vivo Culture Platforms Targeting the Expansion of Human Hematopoietic Stem/Progenitor Cells.

Authors:  André Branco; Sara Bucar; Jorge Moura-Sampaio; Carla Lilaia; Joaquim M S Cabral; Ana Fernandes-Platzgummer; Cláudia Lobato da Silva
Journal:  Front Bioeng Biotechnol       Date:  2020-09-25

Review 3.  Three-Dimensional Avian Hematopoietic Stem Cell Cultures as a Model for Studying Disease Pathogenesis.

Authors:  Vladimir Zmrhal; Andrea Svoradova; Andrej Batik; Petr Slama
Journal:  Front Cell Dev Biol       Date:  2022-01-20

Review 4.  Wharton's jelly-derived stromal cells and their cell therapy applications in allogeneic haematopoietic stem cell transplantation.

Authors:  Cécile Pochon; Anne-Béatrice Notarantonio; Caroline Laroye; Loic Reppel; Danièle Bensoussan; Allan Bertrand; Marie-Thérèse Rubio; Maud D'Aveni
Journal:  J Cell Mol Med       Date:  2022-01-28       Impact factor: 5.310

5.  Transcrystalline growth of PLLA on carbon fiber grafted with nano-SiO2 towards boosting interfacial bonding in bone scaffold.

Authors:  Pei Feng; Jiye Jia; Shuping Peng; Yang Shuai; Hao Pan; Xinna Bai; Cijun Shuai
Journal:  Biomater Res       Date:  2022-01-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.